Login to Your Account

Takeda lands Japan rights for cabozantinib in Exelixis agreement

By Kohei Kanayasu
Staff Writer

Wednesday, February 22, 2017

TOKYO – Exelixis Inc. and Takeda Pharmaceutical Co. Ltd. reached an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription